---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-027311"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2026-08-12T20:08:26+00:00"
generated_at: "2026-08-12T20:09:19.467719+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Talphera Q2 2026 net loss $4.3M; nafamostat CRRT study 75% enrolled

## Summary
- Net loss $4.3M ($0.06/share) vs $3.5M loss ($0.10/share) in Q2 2025; cash/investments $17.1M at June 30, 2026.
- R&D and SG&A expenses combined $3.9M vs $3.7M in Q2 2025, driven by higher Niyad development costs.
- NEPHRO CRRT study of nafamostat 75% enrolled, expected to complete in 2026; all target clinical sites activated.
- KDIGO 2026 draft guidelines cite nafamostat as acceptable CRRT anticoagulant; updated market research estimates 200k annual U.S. CRRT procedures (+21%).
- Regained Nasdaq compliance with $1 bid price rule.

## SEC filing metadata
- accession: 0001437749-26-027311
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2026-08-12T20:08:26+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/0001437749-26-027311-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774926027311/acrx20260811_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-027311
- JSON: https://secwatch.observer/filing/0001437749-26-027311.json
- Plain text: https://secwatch.observer/filing/0001437749-26-027311.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.